An updated HARMONi analysis showed a consistent OS benefit with ivonescimab plus chemotherapy in EGFR-mutated NSCLC.
Quiz|Articles|April 17, 2026
OncLive Weekly News Quiz (4/17/2026): Did You See This Week's Updates in CLL, Pancreatic Cancer, and More?
Author(s)OncLive Staff
Fact checked by: Chris Ryan
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Advertisement
In the phase 3 BRUIN CLL-322 trial (NCT04965493), which evaluated pirtobrutinib (Jaypirca) in combination with venetoclax (Venclexta) and rituximab (Rituxan) vs venetoclax plus rituximab alone in patients with relapsed or refractory chronic lymphocytic leukemia or small lymphocytic lymphoma, what was the primary outcome of the study?
Advertisement
Related to this article
The top 5 OncLive TV videos of the week cover insights in bladder cancer, chronic myeloid leukemia, multiple myeloma, pancreatic cancer, and chronic lymphocytic leukemia.
Laure-Anne Teuwen, MD, PhD, debates the real-world advantages of subcutaneous pembrolizumab.
Iza-bren was approved in China for recurrent or metastatic ESCC following progression on platinum-based chemotherapy and PD-1/PD-L1 inhibition.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Orelabrutinib produced efficacy improvements vs chemoimmunotherapy in previously untreated chronic lymphocytic leukemia.
The phase 3 OptiTROP-Lung06 trial showed a PFS improvement with sac-TMT plus pembrolizumab in PD-L1–negative NSCLC.
The FDA has approved zidesamtinib in patients with locally advanced/metastatic ROS1+ NSCLC who received a prior ROS1 kinase inhibitor.
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Zidesamtinib in Pretreated ROS1+ NSCLC
2
Ivonescimab Plus Chemotherapy Sustains OS Benefit Across Western and Asian Patients in Pretreated EGFR-Mutated NSCLC
3
Sacituzumab Govitecan Yields Responses in Platinum-Resistant Ovarian Cancer
4
How Are Treatment Intensification and Sequencing Reshaping Care in Prostate Cancer and RCC
5